CharlesVWendlingJr.MD

Oncology • Asheville, NC

Hematologist/Oncologist

Join to view full profile

Dr. Wendling is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wendling's full profile

Already have an account?

Office
Charles George VA Medical Center - Asheville, NC
1100 Tunnel Rd
Asheville, NC 28805
Is this information wrong?

Education & Training

Stanford Health CareFellowship, Blood & Bone Marrow Transplant, 2009 - 2010
Louisiana State University School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 1997 - 2000
LSU School of Medicine in ShreveportClass of 1997

Certifications & Licensure

CA State Medical License 2008 - Present
LA State Medical License 2005 - 2025
NC State Medical License 2018 - 2025
AR State Medical License 2002 - 2006
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Ray A. Barlow Scientific Symposium Research Finalist Louisiana State University Health Sciences Center/Feist Weiller Cancer Center, 2008

Clinical Trials

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Start of enrollment: 2005 Apr 14
Completed
Phase 2

Publications & Presentations

Abstracts/Posters

Saftey of Total Therapy II with or without Thalidomide for Newly Diagnosed Myeloma: A study of 475 consecutive patients
Anaissie, E., Jacobson, J., Fassas, A.,Zangari, M., Thertulien, R., Van Rhee, F., Talamo, G., Tricot, G., Wendling, C., Davis, C., Holmig, K., and Barlogie, B., Abstract#1675 Blood, Volume 102, Issue 11
Absence of Hypodiploidy and/or Chromosome 13 Abnormalities (hypo-CA 13) Confers Superior Survival in Multiple Myeloma Patients
Fassas, A.,Sawyer, J., McCoy, J., Anaissie, E., Lee, C.K., Talamo, G., Wendling, C., Zangari, M., Van Rhee, F., Thertulien, R., Tricot, G., and Barlogie, B., Abstract #2534 Blood, Volume 102 Issue 11
Effect of dose of melphalan used in conditioning regimen on outcomes of autologous stem cell transplantation in overweight/obese patients with multiple myeloma.
Elizabeth Ellent, Sachin Gopalkrishn Pai, Ashley Chasick, Qingyang Luo, Charles V. Wendling, Robert Emmons, Journal of Clinical Oncology, Ochsner Medical Center, New Orleans, LA, 2015
A Case of Mixed Phenotype Acute Leukemia.
B. Yan, MD and C. Wendling, MD, Ochsner's Eighth Annual Research Night, Ochsner Clinic Foundation, New Orleans, LA, 5/10/2011
Early Results Total Therapy II for Newly Diagnosed Multiple Myeloma
B. Barlogie, M. Zangari, J. Shaughnessy, J. Jacobson, G. Tricot, J. McCoy, E. Anaissie, A. Fassas, C.K. Lee, R. Thertulien, F. van Rhee, F. Muwalla, C. Wendling, J. Ep..., Eleventh Internaltional ABMT Symposium, Arlington, TX
Inpatient Pharmaceutical Cost of Hematological Agents: A Single Center Report
C. Wendling, J. Glass, and P. Rigby, Abstract #5491 Blood, Volume 108, Issue 11
Activity of Tyrosine Kinase Inhibitors in Multiple Myeloma
R. Munker, C. Cordova, P. Polk, C. Wendling, A. Sun, J. Cardelli., Abstract #4804 Blood, Volume 110 Issue 11
Effects of hyperglycemia and dexamethasone on expression of thioreduxin-interacting protein (TXNIP) expression and reactive oxygen species (ROS) in multiple myeloma – ...
E. Friday, C. Wendling, J. Ledet, F. Turturro, 2008 AACR Annual Meeting, San Diego, CA
Join now to see all